Insider Selling: Chemours Co (CC) VP Sells 9,049 Shares of Stock

Chemours Co (NYSE:CC) VP Amy Trojanowski sold 9,049 shares of Chemours stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $39.10, for a total transaction of $353,815.90. Following the sale, the vice president now owns 54,795 shares of the company’s stock, valued at $2,142,484.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Amy Trojanowski also recently made the following trade(s):

  • On Wednesday, March 13th, Amy Trojanowski sold 10,129 shares of Chemours stock. The shares were sold at an average price of $39.10, for a total transaction of $396,043.90.
  • On Friday, March 1st, Amy Trojanowski sold 13,536 shares of Chemours stock. The shares were sold at an average price of $38.63, for a total transaction of $522,895.68.

Shares of NYSE:CC traded down $0.72 during trading on Friday, hitting $37.89. 2,267,865 shares of the stock traded hands, compared to its average volume of 1,629,077. The company has a debt-to-equity ratio of 3.88, a current ratio of 1.93 and a quick ratio of 1.26. The firm has a market cap of $6.46 billion, a price-to-earnings ratio of 6.68, a price-to-earnings-growth ratio of 0.53 and a beta of 2.31. Chemours Co has a 52-week low of $25.17 and a 52-week high of $53.25.



Chemours (NYSE:CC) last posted its earnings results on Thursday, February 14th. The specialty chemicals company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $1.04 by $0.01. The firm had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.53 billion. Chemours had a net margin of 14.99% and a return on equity of 98.83%. The business’s quarterly revenue was down 7.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.19 EPS. On average, sell-side analysts anticipate that Chemours Co will post 4.69 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 15th. Stockholders of record on Wednesday, February 27th will be issued a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 2.64%. The ex-dividend date is Tuesday, February 26th. Chemours’s dividend payout ratio (DPR) is 17.64%.

Several analysts have commented on CC shares. Zacks Investment Research cut shares of Chemours from a “hold” rating to a “sell” rating in a research note on Friday, January 4th. Susquehanna Bancshares restated a “neutral” rating and set a $37.00 price objective on shares of Chemours in a research note on Tuesday, February 19th. SunTrust Banks lifted their price objective on shares of Chemours to $40.00 and gave the company a “hold” rating in a research note on Tuesday, February 19th. HSBC assumed coverage on shares of Chemours in a research note on Tuesday, January 8th. They set a “buy” rating and a $52.00 price objective for the company. Finally, Barclays reaffirmed a “buy” rating and set a $48.00 target price on shares of Chemours in a report on Tuesday, January 15th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company’s stock. Chemours has a consensus rating of “Hold” and a consensus target price of $48.13.

A number of hedge funds and other institutional investors have recently modified their holdings of CC. Oregon Public Employees Retirement Fund increased its holdings in Chemours by 3,583.3% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 2,675,256 shares of the specialty chemicals company’s stock worth $95,000 after acquiring an additional 2,602,624 shares in the last quarter. FMR LLC increased its holdings in Chemours by 10.5% in the 3rd quarter. FMR LLC now owns 26,450,684 shares of the specialty chemicals company’s stock worth $1,043,214,000 after acquiring an additional 2,523,555 shares in the last quarter. Iridian Asset Management LLC CT increased its holdings in Chemours by 34.9% in the 3rd quarter. Iridian Asset Management LLC CT now owns 9,420,415 shares of the specialty chemicals company’s stock worth $371,541,000 after acquiring an additional 2,439,293 shares in the last quarter. Norges Bank purchased a new stake in Chemours in the 4th quarter worth $46,624,000. Finally, LSV Asset Management increased its holdings in Chemours by 57.5% in the 4th quarter. LSV Asset Management now owns 3,081,906 shares of the specialty chemicals company’s stock worth $86,971,000 after acquiring an additional 1,124,997 shares in the last quarter. 79.49% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Chemours Co (CC) VP Sells 9,049 Shares of Stock” was first published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://dakotafinancialnews.com/2019/03/16/insider-selling-chemours-co-cc-vp-sells-9049-shares-of-stock.html.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.

See Also: What are retained earnings?

Insider Buying and Selling by Quarter for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.